June 30, 2014
/PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on
As previously announced, on
February 17, 2014
, Actavis, Forest, Tango US Holdings Inc., Tango Merger Sub 1 LLC and Tango Merger Sub 2 LLC, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, Forest stockholders were entitled to elect to receive, (i) .3306 of an Actavis ordinary share and
in cash, without interest (the "Standard Election Consideration"), (ii) .4723 of an Actavis ordinary share, subject to proration and allocation procedures set forth in the Merger Agreement (the "Stock Election Consideration") or (iii)
in cash, without interest, subject to proration and allocation procedures set forth in the Merger Agreement (the "Cash Election Consideration"), in exchange for each share of Forest common stock. The deadline for making this election was
New York City
June 27, 2014
(the "Election Deadline").
Based on available information as of the Election Deadline, the preliminary merger consideration election results are as follows:
- Holders of approximately 13.81% of the outstanding shares of Forest common stock, or 37,487,783 shares of common stock, elected the Standard Election Consideration.
- Holders of approximately 0.44% of the outstanding shares of Forest common stock, or 1,202,340 shares of common stock, elected the Cash Election Consideration.
- Holders of approximately 72.78% of the outstanding shares of Forest common stock, or 197,607,707 shares of common stock, elected the Stock Election Consideration.
Holders of approximately 12.97% of the outstanding shares of Forest common stock, or 35,228,456 shares of common stock, failed to make a valid election prior to the Election Deadline, and therefore are deemed to have elected the Standard Election Consideration. Because the Stock Election Consideration option was substantially oversubscribed, the consideration to be received by the holders who elected the Stock Election Consideration will be prorated pursuant to the terms set forth in the Merger Agreement and as further described in the Joint Proxy Statement/Prospectus of Actavis and Forest, dated
, 2014. After the final results of the merger consideration election process are determined, the final allocation of merger consideration will be calculated in accordance with the terms of the Merger Agreement.
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in
and U.S. administrative headquarters in
Parsippany, New Jersey
Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter (OTC) pharmaceutical products and has commercial operations in approximately 60 countries. The Company's North American branded pharmaceuticals business is focused principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories with a strong pipeline of products in various stages of development. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.